T-cell distribution and adhesion receptor expression in metastatic melanoma
C Weishaupt, KN Munoz, E Buzney, TS Kupper… - Clinical Cancer …, 2007 - AACR
C Weishaupt, KN Munoz, E Buzney, TS Kupper, RC Fuhlbrigge
Clinical Cancer Research, 2007•AACRPurpose: Metastatic malignant melanoma is a devastating disease with a poor prognosis.
Recent therapeutic trials have focused on immunotherapy to induce development of
endogenous antitumor immune responses. To date, such protocols have shown success in
activation of tumor-specific CTL but no overall improvement in survival. To kill tumor, antigen-
specific CTL must efficiently target and enter tumor tissue. The purpose of this study was to
examine the pathway of leukocyte migration to metastatic melanoma. Experimental design …
Recent therapeutic trials have focused on immunotherapy to induce development of
endogenous antitumor immune responses. To date, such protocols have shown success in
activation of tumor-specific CTL but no overall improvement in survival. To kill tumor, antigen-
specific CTL must efficiently target and enter tumor tissue. The purpose of this study was to
examine the pathway of leukocyte migration to metastatic melanoma. Experimental design …
Abstract
Purpose: Metastatic malignant melanoma is a devastating disease with a poor prognosis. Recent therapeutic trials have focused on immunotherapy to induce development of endogenous antitumor immune responses. To date, such protocols have shown success in activation of tumor-specific CTL but no overall improvement in survival. To kill tumor, antigen-specific CTL must efficiently target and enter tumor tissue. The purpose of this study was to examine the pathway of leukocyte migration to metastatic melanoma.
Experimental design: Peripheral blood and metastatic melanoma tissues (n = 65) were evaluated for expression of adhesion molecules using immunohistochemistry of tumor sections and flow cytometry of tumor-associated and peripheral blood CTL and compared with healthy controls. CTL expressing T-cell receptors for the melanoma antigen MART-1 were identified in a subset of samples by reactivity with HLA-A2 tetramers loaded with MART-1 peptide.
Results: Results show that the majority of metastatic melanoma samples examined do not express the vascular adhesion receptors E-selectin (CD62E), P-selectin (CD62P), and intercellular adhesion molecule-1 (CD54) on vessels within the tumor boundaries. Strong adhesion receptor expression was noted on vessels within adjacent tissue. Tumor-associated T lymphocytes accumulate preferentially in these adjacent areas and are not enriched for skin- or lymph node–homing receptor phenotype.
Conclusion: Expression of leukocyte homing receptors is dysregulated on the vasculature of metastatic melanoma. This results in a block to recruitment of activated tumor-specific CTL to melanoma metastases and is a likely factor limiting the effectiveness of current immunotherapy protocols.
AACR
